Climb Bio (CLYM) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Climb Bio (CLYM) has outperformed Nuvectis Pharma (NVCT) over the past year, gaining 549.1% versus a gain of 223.1%. Nuvectis Pharma is the larger company by market cap ($657.1 million vs $623.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | NVCT |
|---|---|---|
| Share price | $10.86 | $20.13 |
| Market cap | $623.76M | $657.12M |
| 1-day change | +1.40% | -0.79% |
| YTD return | +167.75% | +166.62% |
| 1-year return | +549.09% | +223.11% |
| 5-year return | -33.64% | — |
| EPS (TTM) | $-0.82 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $29.28 |
| 52-week low | $1.64 | $5.55 |
| Distance from 52-week high | -40.75% | -31.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +153.87% | +75.86% |
| Average volume | 1.37M | 215.43K |
| Shares outstanding | 57.44M | 32.64M |
| Employees | 28 | 16 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed NVCT by 326.0 percentage points over the past year.
- The two companies sit in different sectors: Climb Bio in Health Care and Nuvectis Pharma in Healthcare.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
CLYM vs NVCT FAQ
Which is bigger, Climb Bio or Nuvectis Pharma?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $657.12M compared with $623.76M for Climb Bio (CLYM).
Which stock has performed better over the past year, CLYM or NVCT?
CLYM returned +549.09% over the past 12 months, compared with +223.11% for NVCT (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Nuvectis Pharma in the same industry?
No. Climb Bio is in the Health Care sector, while Nuvectis Pharma is in Healthcare.